Market closedNon-fractional
Arcutis Biotherapeutics/ARQT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Ticker
ARQT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Westlake Village, United States
Employees
296
Website
www.arcutis.com
ARQT Metrics
BasicAdvanced
$1.2B
Market cap
-
P/E ratio
-$2.66
EPS
1.18
Beta
-
Dividend rate
Price and volume
Market cap
$1.2B
Beta
1.18
Financial strength
Current ratio
9.894
Quick ratio
9.322
Long term debt to equity
91.572
Total debt to equity
91.908
Interest coverage (TTM)
-6.52%
Management effectiveness
Return on assets (TTM)
-28.62%
Return on equity (TTM)
-119.24%
Valuation
Price to revenue (TTM)
7.763
Price to book
5.18
Price to tangible book (TTM)
5.32
Price to free cash flow (TTM)
-4.157
Growth
Revenue change (TTM)
1,545.18%
Earnings per share change (TTM)
-53.12%
3-year earnings per share growth (CAGR)
-8.49%
What the Analysts think about ARQT
Analyst Ratings
Majority rating from 7 analysts.
ARQT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$50M
266.67%
Net income
-$35M
-46.68%
Profit margin
-71.31%
-85.46%
ARQT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.16
-$0.73
-$0.72
-$0.32
-
Expected
-$1.25
-$0.86
-$0.78
-$0.73
-$0.57
Surprise
-7.21%
-14.87%
-7.10%
-56.16%
-
ARQT News
AllArticlesVideos
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
GlobeNewsWire·4 days ago
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
GlobeNewsWire·2 weeks ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcutis Biotherapeutics stock?
Arcutis Biotherapeutics (ARQT) has a market cap of $1.2B as of July 26, 2024.
What is the P/E ratio for Arcutis Biotherapeutics stock?
The price to earnings (P/E) ratio for Arcutis Biotherapeutics (ARQT) stock is 0 as of July 26, 2024.
Does Arcutis Biotherapeutics stock pay dividends?
No, Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Arcutis Biotherapeutics dividend payment date?
Arcutis Biotherapeutics (ARQT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcutis Biotherapeutics?
Arcutis Biotherapeutics (ARQT) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Arcutis Biotherapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.